Regeneron Pharmaceuticals, Inc. is a Tarrytown, New York biotechnology company founded in 1988 by Leonard S. Schleifer and George D. Yancopoulos. The company reported FY2025 revenue of about $14.34 billion and GAAP net income of about $4.50 billion, with more than 15,400 employees.
What Regeneron Does
Regeneron discovers, develops, manufactures, and commercializes medicines for serious diseases. Its best-known products and collaborations include EYLEA and EYLEA HD for retinal disease, Dupixent with Sanofi for Type 2 inflammatory diseases, Libtayo in oncology, and additional rare-disease and specialty medicines.
How Regeneron Makes Money
The business model combines direct product sales with collaboration economics. U.S. EYLEA and EYLEA HD sales remain central, while Dupixent is recorded by Sanofi but produces important profit-share and collaboration revenue for Regeneron. Bayer commercializes EYLEA outside the United States. This structure gives Regeneron both direct commercial exposure and partner-supported global scale.
Strategy and Risks
The strategic question is whether Regeneron can defend EYLEA, keep benefiting from Dupixent growth, and create the next wave of approvals from oncology, obesity, rare disease, gene therapy, and cell therapy. The risk is concentration. If ophthalmology competition or pipeline setbacks move faster than new launches, the revenue mix can become harder to grow.
Acquisitions and Pipeline Context
Regeneron's acquisitions are targeted additions to a science-led model. Checkmate added investigational immuno-oncology work, Decibel added hearing-loss gene therapy programs, and the 2seventy bio transaction helped form Regeneron Cell Medicines. Importantly, DB-OTO is not an approved product; Regeneron describes it as investigational and being studied in the Phase 1/2 CHORD trial.
Deeper Analysis: Why Regeneron Is Different
Regeneron's most important distinction is that it is not mainly a licensing shell around other companies' drugs. It has a long-running internal discovery culture, its own biologics manufacturing capability, and a management team still anchored by the same scientific founders who built the company. That matters because biotechnology value can disappear quickly when a company depends on one externally sourced asset. Regeneron's best periods came when the discovery platform, commercial execution, and partnerships reinforced each other.
The cleanest example is the relationship between EYLEA and Dupixent. EYLEA made Regeneron a scaled commercial company, but it also created concentration risk as newer branded competitors and biosimilars challenged the franchise. Dupixent created a different kind of engine: Sanofi records global net sales, while Regeneron participates economically through the collaboration. That gives Regeneron exposure to a large immunology brand without bearing every commercial cost alone. A useful reader takeaway is that Regeneron revenue is not the same thing as total patient demand for every important medicine tied to the company.
Regeneron's acquisition strategy should be read through that lens. Checkmate, Decibel, and the 2seventy bio cell-therapy transaction are not proof that Regeneron has become a roll-up. They are targeted efforts to add modalities and specialized teams where the internal platform can benefit from outside science. The Decibel correction is especially important: DB-OTO is an investigational gene therapy in the Phase 1/2 CHORD trial, not an approved product and not a current commercial revenue source. Treating it as approved would overstate both clinical certainty and near-term financial contribution.
What To Watch Next
The next few years depend on three questions. First, can EYLEA HD slow the erosion of the older EYLEA franchise? Second, can Dupixent keep adding indications and patients at a pace that sustains collaboration growth? Third, can oncology, rare disease, and genetic medicine produce enough new approvals to reduce concentration. Regeneron has the balance sheet and scientific history to keep investing, but biotech investors should separate proven revenue from clinical possibility.
That separation is the point of this refresh. The page now distinguishes approved medicines from investigational programs, identifies the source-backed revenue base, and treats acquisitions as pipeline expansion rather than guaranteed product success.
